{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:34:56Z","timestamp":1762079696914,"version":"3.37.3"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T00:00:00Z","timestamp":1563148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T00:00:00Z","timestamp":1563148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s00259-019-04417-1","type":"journal-article","created":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T10:51:44Z","timestamp":1563187904000},"page":"2311-2321","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate 177Lu-NNV003"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5282-6571","authenticated-orcid":false,"given":"Astri Fjelde","family":"Maaland","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Heyerdahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"O\u2019Shea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bergthora","family":"Eiriksdottir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9ronique","family":"Pascal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan Terje","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arne","family":"Kolstad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jostein","family":"Dahle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,15]]},"reference":[{"issue":"5","key":"4417_CR1","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359\u2013E86.","journal-title":"Int J Cancer"},{"issue":"19","key":"4417_CR2","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","volume":"116","author":"M Sant","year":"2010","unstructured":"Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116(19):3724\u201334.","journal-title":"Blood."},{"issue":"suppl_4","key":"4417_CR3","doi-asserted-by":"publisher","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","volume":"28","author":"M Dreyling","year":"2017","unstructured":"Dreyling M, Campo E, Hermine O, Jerkeman M, Le Gouill S, Rule S, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv62\u201371.","journal-title":"Ann Oncol"},{"issue":"Suppl 5","key":"4417_CR4","doi-asserted-by":"publisher","first-page":"v78","DOI":"10.1093\/annonc\/mdv303","volume":"26","author":"B Eichhorst","year":"2015","unstructured":"Eichhorst B, Robak T, Montserrat E, Ghia P, Hillmen P, Hallek M, et al. Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v78\u201384.","journal-title":"Ann Oncol"},{"issue":"Suppl 5","key":"4417_CR5","doi-asserted-by":"publisher","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","volume":"26","author":"H Tilly","year":"2015","unstructured":"Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v116\u201325.","journal-title":"Ann Oncol"},{"key":"4417_CR6","unstructured":"ESMO Guidlines committee: eUpdate \u2013 chronic lymphocytic Leukaemia treatment recommendations. 2017. http:\/\/www.esmo.org\/Guidelines\/Haematological-Malignancies\/Chronic-Lymphocytic-Leukaemia\/eUpdate-Treatment-Recommendations . Accessed 11 Nov 2017."},{"key":"4417_CR7","doi-asserted-by":"crossref","unstructured":"Epperla N, Hamadani M, Fenske TS, Costa LJ. Incidence and survival trends in mantle cell lymphoma. Br J Haematol. 2017;181(5):703\u2013706.","DOI":"10.1111\/bjh.14699"},{"issue":"9","key":"4417_CR8","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S1470-2045(14)70282-7","volume":"15","author":"M Sant","year":"2014","unstructured":"Sant M, Minicozzi P, Mounier M, Anderson LA, Brenner H, Holleczek B, et al. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. The Lancet Oncology. 2014;15(9):931\u201342.","journal-title":"The Lancet Oncology"},{"issue":"22","key":"4417_CR9","doi-asserted-by":"publisher","first-page":"5027","DOI":"10.1200\/JCO.2005.09.137","volume":"23","author":"LH Sehn","year":"2005","unstructured":"Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005;23(22):5027\u201333.","journal-title":"J Clin Oncol"},{"issue":"24","key":"4417_CR10","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1056\/NEJMc1402716","volume":"370","author":"RR Furman","year":"2014","unstructured":"Furman RR, Cheng S, Lu P, Setty M, Perez AR, Guo A, et al. Ibrutinib resistance in chronic lymphocytic leukemia. N Engl J Med. 2014;370(24):2352\u20134.","journal-title":"N Engl J Med"},{"issue":"1","key":"4417_CR11","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41467-018-03170-7","volume":"9","author":"CD Herling","year":"2018","unstructured":"Herling CD, Abedpour N, Weiss J, Schmitt A, Jachimowicz RD, Merkel O, et al. Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia. Nat Commun. 2018;9(1):727.","journal-title":"Nat Commun"},{"issue":"2","key":"4417_CR12","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.beha.2011.02.009","volume":"24","author":"AR Rezvani","year":"2011","unstructured":"Rezvani AR, Maloney DG. Rituximab resistance. Best Pract Res Clin Haematol. 2011;24(2):203\u201316.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"12","key":"4417_CR13","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1001\/jamainternmed.2014.5756","volume":"174","author":"V Prasad","year":"2014","unstructured":"Prasad V. The withdrawal of drugs for commercial reasons: the incomplete story of tositumomab. JAMA Intern Med. 2014;174(12):1887\u20138.","journal-title":"JAMA Intern Med"},{"issue":"3","key":"4417_CR14","doi-asserted-by":"crossref","first-page":"905","DOI":"10.4049\/jimmunol.140.3.905","volume":"140","author":"R Schwartz-Albiez","year":"1988","unstructured":"Schwartz-Albiez R, Dorken B, Hofmann W, Moldenhauer G. The B cell-associated CD37 antigen (gp40-52). Structure and subcellular expression of an extensively glycosylated glycoprotein. J Immunol. 1988;140(3):905\u201314.","journal-title":"J Immunol"},{"issue":"7","key":"4417_CR15","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1038\/leu.2014.32","volume":"28","author":"KA Beckwith","year":"2014","unstructured":"Beckwith KA, Frissora FW, Stefanovski MR, Towns WH, Cheney C, Mo X, et al. The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model. Leukemia. 2014;28(7):1501\u201310.","journal-title":"Leukemia."},{"issue":"20","key":"4417_CR16","doi-asserted-by":"publisher","first-page":"3500","DOI":"10.1182\/blood-2013-05-505685","volume":"122","author":"J Deckert","year":"2013","unstructured":"Deckert J, Park PU, Chicklas S, Yi Y, Li M, Lai KC, et al. A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies. Blood. 2013;122(20):3500\u201310.","journal-title":"Blood."},{"issue":"15","key":"4417_CR17","doi-asserted-by":"publisher","first-page":"4159","DOI":"10.1182\/blood-2011-04-351932","volume":"118","author":"K-H Heider","year":"2011","unstructured":"Heider K-H, Kiefer K, Zenz T, Volden M, Stilgenbauer S, Ostermann E, et al. A novel fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies. Blood. 2011;118(15):4159\u201368.","journal-title":"Blood."},{"issue":"1","key":"4417_CR18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/bjh.13099","volume":"168","author":"JM Pagel","year":"2015","unstructured":"Pagel JM, Spurgeon SE, Byrd JC, Awan FT, Flinn IW, Lanasa MC, et al. Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR\u2122 therapeutic protein, for relapsed or refractory NHL patients. Br J Haematol. 2015;168(1):38\u201345.","journal-title":"Br J Haematol"},{"issue":"7","key":"4417_CR19","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1158\/1535-7163.MCT-15-0067","volume":"14","author":"DS Pereira","year":"2015","unstructured":"Pereira DS, Guevara CI, Jin L, Mbong N, Verlinsky A, Hsu SJ, et al. AGS67E, an anti-CD37 monomethyl Auristatin E antibody-drug conjugate as a potential therapeutic for B\/T-cell malignancies and AML: a new role for CD37 in AML. Mol Cancer Ther. 2015;14(7):1650\u201360.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"4417_CR20","first-page":"85","volume":"33","author":"J Dahle","year":"2013","unstructured":"Dahle J, Repetto-Llamazares AH, Mollatt CS, Melhus KB, Bruland OS, Kolstad A, et al. Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin\u2019s lymphoma. Anticancer Res. 2013;33(1):85\u201395.","journal-title":"Anticancer Res"},{"issue":"Suppl 1","key":"4417_CR21","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1182\/blood-2018-99-110555","volume":"132","author":"A Kolstad","year":"2018","unstructured":"Kolstad A, Madsbu U, Beasley M, Bayne M, Illidge TM, O\u2019Rourke N, et al. LYMRIT 37-01: a phase I\/II study of 177lu-Lilotomab Satetraxetan (Betalutin\u00ae) antibody-radionuclide-conjugate (ARC) for the treatment of relapsed non-Hodgkin\u2019s lymphoma (NHL) \u2014 analysis with 6-month follow-up. Blood. 2018;132(Suppl 1):2879.","journal-title":"Blood."},{"issue":"4","key":"4417_CR22","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/ejh.13139","volume":"101","author":"AHV Repetto-Llamazares","year":"2018","unstructured":"Repetto-Llamazares AHV, Malenge MM, O\u2019Shea A, Eiriksdottir B, Stokke T, Larsen RH, et al. Combination of (177) Lu-lilotomab with rituximab significantly improves the therapeutic outcome in preclinical models of non-Hodgkin\u2019s lymphoma. Eur J Haematol. 2018;101(4):522\u201331.","journal-title":"Eur J Haematol"},{"issue":"27","key":"4417_CR23","doi-asserted-by":"publisher","first-page":"22927","DOI":"10.1074\/jbc.M112.355131","volume":"287","author":"JT Andersen","year":"2012","unstructured":"Andersen JT, Foss S, Kenanova VE, Olafsen T, Leikfoss IS, Roopenian DC, et al. Anti-carcinoembryonic antigen single-chain variable fragment antibody variants bind mouse and human neonatal fc receptor with different affinities that reveal distinct cross-species differences in serum half-life. J Biol Chem. 2012;287(27):22927\u201337.","journal-title":"J Biol Chem"},{"issue":"1","key":"4417_CR24","doi-asserted-by":"publisher","first-page":"20","DOI":"10.2174\/1874471011306010004","volume":"6","author":"AH Repetto-Llamazares","year":"2013","unstructured":"Repetto-Llamazares AH, Larsen RH, Mollatt C, Lassmann M, Dahle J. Biodistribution and dosimetry of (177)Lu-tetulomab, a new radioimmunoconjugate for treatment of non-Hodgkin lymphoma. Curr Radiopharm. 2013;6(1):20\u20137.","journal-title":"Curr Radiopharm"},{"issue":"7","key":"4417_CR25","doi-asserted-by":"publisher","first-page":"4826","DOI":"10.1074\/jbc.M109.081828","volume":"285","author":"JT Andersen","year":"2010","unstructured":"Andersen JT, Daba MB, Berntzen G, Michaelsen TE, Sandlie I. Cross-species binding analyses of mouse and human neonatal fc receptor show dramatic differences in immunoglobulin G and albumin binding. J Biol Chem. 2010;285(7):4826\u201336.","journal-title":"J Biol Chem"},{"issue":"12","key":"4417_CR26","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/intimm\/13.12.1551","volume":"13","author":"RJ Ober","year":"2001","unstructured":"Ober RJ, Radu CG, Ghetie V, Ward ES. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol. 2001;13(12):1551\u20139.","journal-title":"Int Immunol"},{"issue":"5","key":"4417_CR27","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1080\/19420862.2017.1323159","volume":"9","author":"G Dekkers","year":"2017","unstructured":"Dekkers G, Bentlage AEH, Stegmann TC, Howie HL, Lissenberg-Thunnissen S, Zimring J, et al. Affinity of human IgG subclasses to mouse fc gamma receptors. mAbs. 2017;9(5):767\u201373.","journal-title":"mAbs."},{"issue":"7","key":"4417_CR28","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.4049\/jimmunol.1200356","volume":"189","author":"MB Overdijk","year":"2012","unstructured":"Overdijk MB, Verploegen S, Ortiz Buijsse A, Vink T, Leusen JH, Bleeker WK, et al. Crosstalk between human IgG isotypes and murine effector cells. J Immunol. 2012;189(7):3430\u20138.","journal-title":"J Immunol"},{"issue":"1","key":"4417_CR29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s002620050456","volume":"46","author":"N Reddy","year":"1998","unstructured":"Reddy N, Lin Ong G, Behr TM, Sharkey RM, Goldenberg DM, Mattes MJ. Rapid blood clearance of mouse IgG2a and human IgG1 in many nude and nu\/+ mouse strains is due to low IgG2a serum concentrations. Cancer Immunol Immunother. 1998;46(1):25\u201333.","journal-title":"Cancer Immunol Immunother"},{"issue":"19","key":"4417_CR30","doi-asserted-by":"publisher","first-page":"6935","DOI":"10.1088\/0031-9155\/61\/19\/6935","volume":"61","author":"S Marcatili","year":"2016","unstructured":"Marcatili S, Pichard A, Courteau A, Ladjohounlou R, Navarro-Teulon I, Repetto-Llamazares A, et al. Realistic multi-cellular dosimetry for 177Lu-labelled antibodies: model and application. Phys Med Biol. 2016;61(19):6935\u201352.","journal-title":"Phys Med Biol"},{"issue":"1","key":"4417_CR31","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2174\/1874226200902010079","volume":"2","author":"JE Belizario","year":"2009","unstructured":"Belizario JE. Immunodeficient mouse models: an overview. Open Immunol J. 2009;2(1):79\u201385.","journal-title":"Open Immunol J"},{"issue":"1","key":"4417_CR32","doi-asserted-by":"crossref","first-page":"180","DOI":"10.4049\/jimmunol.154.1.180","volume":"154","author":"LD Shultz","year":"1995","unstructured":"Shultz LD, Schweitzer PA, Christianson SW, Gott B, Schweitzer IB, Tennent B, et al. Multiple defects in innate and adaptive immunologic function in NOD\/LtSz-scid mice. J Immunol. 1995;154(1):180\u201391.","journal-title":"J Immunol"},{"issue":"7","key":"4417_CR33","doi-asserted-by":"publisher","first-page":"e103070","DOI":"10.1371\/journal.pone.0103070","volume":"9","author":"AH Repetto-Llamazares","year":"2014","unstructured":"Repetto-Llamazares AH, Larsen RH, Giusti AM, Riccardi E, Bruland OS, Selbo PK, et al. 177Lu-DOTA-HH1, a novel anti-CD37 radio-Immunoconjugate: a study of toxicity in nude mice. PLoS One. 2014;9(7):e103070.","journal-title":"PLoS One"},{"issue":"4","key":"4417_CR34","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1509981","volume":"374","author":"JC Byrd","year":"2016","unstructured":"Byrd JC, Harrington B, O\u2019Brien S, Jones JA, Schuh A, Devereux S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):323\u201332.","journal-title":"N Engl J Med"},{"issue":"8","key":"4417_CR35","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","volume":"35","author":"MS Davids","year":"2017","unstructured":"Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, et al. Phase I first-in-human study of Venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol. 2017;35(8):826\u201333.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4417_CR36","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S1470-2045(14)71182-9","volume":"16","author":"MZ Farooqui","year":"2015","unstructured":"Farooqui MZ, Valdez J, Martyr S, Aue G, Saba N, Niemann CU, et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol. 2015;16(2):169\u201376.","journal-title":"Lancet Oncol"},{"issue":"1","key":"4417_CR37","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/S1470-2045(13)70513-8","volume":"15","author":"S O\u2019Brien","year":"2014","unstructured":"O\u2019Brien S, Furman RR, Coutre SE, Sharman JP, Burger JA, Blum KA, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b\/2 trial. Lancet Oncol. 2014;15(1):48\u201358.","journal-title":"Lancet Oncol."},{"issue":"4","key":"4417_CR38","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"AW Roberts","year":"2016","unstructured":"Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. Targeting BCL2 with Venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311\u201322.","journal-title":"N Engl J Med"},{"issue":"10121","key":"4417_CR39","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","volume":"391","author":"M Wang","year":"2018","unstructured":"Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018;391(10121):659\u201367.","journal-title":"Lancet."},{"issue":"6","key":"4417_CR40","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507\u201316.","journal-title":"N Engl J Med"},{"issue":"1","key":"4417_CR41","doi-asserted-by":"publisher","first-page":"48","DOI":"10.2967\/jnumed.116.173922","volume":"58","author":"J Blakkisrud","year":"2017","unstructured":"Blakkisrud J, Londalen A, Martinsen AC, Dahle J, Holtedahl JE, Bach-Gansmo T, et al. Tumor-absorbed dose for non-Hodgkin lymphoma patients treated with the anti-CD37 antibody radionuclide conjugate 177Lu-Lilotomab Satetraxetan. J Nucl Med. 2017;58(1):48\u201354.","journal-title":"J Nucl Med"},{"issue":"13","key":"4417_CR42","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1200\/JCO.2003.09.542","volume":"21","author":"RL Haas","year":"2003","unstructured":"Haas RL, Poortmans P, de Jong D, Aleman BM, Dewit LG, Verheij M, et al. High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. J Clin Oncol. 2003;21(13):2474\u201380.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4417_CR43","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.1939-165X.2011.00287.x","volume":"40","author":"A Geffr\u00e9","year":"2011","unstructured":"Geffr\u00e9 A, Concordet D, Braun J-P, Trumel C. Reference value advisor: a new freeware set of macroinstructions to calculate reference intervals with Microsoft excel. Vet Clin Pathol. 2011;40(1):107\u201312.","journal-title":"Vet Clin Pathol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-019-04417-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-019-04417-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-019-04417-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T07:59:03Z","timestamp":1695023943000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-019-04417-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,15]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["4417"],"URL":"https:\/\/doi.org\/10.1007\/s00259-019-04417-1","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"type":"print","value":"1619-7070"},{"type":"electronic","value":"1619-7089"}],"subject":[],"published":{"date-parts":[[2019,7,15]]},"assertion":[{"value":"21 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Jostein Dahle, Helen Heyerdahl, Adam O\u2019Shea and V\u00e9ronique Pascal are employees and shareholders of Nordic Nanovector ASA. Astri Fjelde Maaland is a PhD student employed by Nordic Nanovector ASA, funded by the Norwegian Research Council. Arne Kolstad is a member of the Scientific Advisory Board of Nordic Nanovector ASA. Bergthora Eiriksdottir and Jan Terje Andersen have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All applicable international, national, and institutional guidelines for the care and use of animals were followed. Animal studies were approved by the National Animal Research Authorities. This article does not contain any studies with human participants performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}